ESCRS - P173 - A RETROSPECTIVE DATA REVIEW CONFIRMS THAT TOPICAL PRESERVATIVE-FREE HYDROCORTISONE IMPROVES INFLAMMATION IN DRY EYE DISEASE

A RETROSPECTIVE DATA REVIEW CONFIRMS THAT TOPICAL PRESERVATIVE-FREE HYDROCORTISONE IMPROVES INFLAMMATION IN DRY EYE DISEASE

Published 2022 - 26th ESCRS Winter Meeting

Reference: P173 | Type: Abstracts | DOI: 10.82333/4y14-we41

Authors: Leon Markovic* 1

1University Eye Department,University Hospital "Sveti Duh",Zagreb,Croatia

Purpose

Inflammation is among the most important mechanisms in the pathogenesis of dry eye disease (DED), triggering the vicious circle of the disease. Reducing inflammation is an important target in dry eye disease treatment. Hydrocortisone is a low-potency corticosteroid with a low ocular penetration potential. The aim was to document the effect of topical preservative-free hydrocortisone 0.335% (PFH, Softacort®, Laboratoires Théa, France) on DED.

Setting

Retrospective data review of patients with mild to moderate DED, treated with PFH for 15 days.

Methods

Clinical evaluations at Days 0 and 15 included the assessment of the central precorneal tear film thickness (CPTFT), fluorescein tear breakup time, Schirmer test, corneal grading staining (Oxford schema), ocular surface disease index (OSDI) spatial distribution of the precorneal tear film thickness, intraocular pressure (IOP) and local tolerance.

Results

Data from 13 women and 2 men were collected. Mean age±SD was 51±5 years for women and 53±4 years for men. Clinical signs and symptoms significantly (all p<0.05) improved after 15 days of treatment. A significant positive correlation between the percentage of change in left eye CPTFT and that in the contralateral eye CPTFT was observed (p=0.003) as well as for both eyes and the left eye FTBUT (p=0.03). For the percentage of change in OSDI, the only significant correlation was with the percentage of change in right eye and FTBUT (p=0.03). IOP remained unchanged. No adverse events were recorded.

Conclusion

This retrospective data review confirms that topical PFH twice daily for 2 weeks significantly improves clinical signs and symptoms in patients with mild to moderate DED with no safety issues.